The trial of two potential treatments for the Bundibugyo species of Ebola behind the deadly outbreak in the DR Congo began in the country on Thursday, the World Health Organization said.

There are no approved vaccines or treatments for the rare strain which has been spreading in the northeastern provinces of the Democratic Republic of Congo.

There have been 1,406 confirmed cases and 438 confirmed deaths in the DRC, while 208 people have recovered from the virus, according to figures from the WHO.

"Today, the clinical trial of two therapeutics began, with the enrollment of the first patient," WHO chief Tedros Adhanom Ghebreyesus told reporters.

The trial is evaluating the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination.

"Patients who enroll in the trial will receive comprehensive supportive care and close follow up," Tedros insisted.

"We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial."

Trial could take several months

The outbreak is heavily centred in the DRC's Ituri province.

Vasee Moorthy, who leads the WHO's research and development blueprint arm, said the trial would begin in one treatment facility in Ituri before gradually expanding to others in the province.

He said patients would be randomised into four groups: those who receive remdesivir; MBP134; neither; or both, to see if combination provides additional benefits.

The numbers of patients required would depend of how effective the therapeutics appear to be: the more effective they are, the fewer patients who would be needed, Moorthy said.

He said the trial would take months and could even run into next year, and might require more than 1,000 patients to produce definitive answers.

He said the trial already had enough remdesivir and MBP134 for 1,200 patients to be enrolled.

Ensuring post-trial access to any product that proves safe and efficacious "is absolutely central to our thinking", he insisted.

The case fatality rate in the DRC is currently 31 percent.

"Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit," said Tedros.

Treatment centre torched

The WHO meanwhile said the Ebola response was facing many challenges, taking place against the backdrop of a region ravaged by conflict, with pre-existing deep humanitarian needs.

Tedros said the outbreak was continuing to expand, with an average of 38 new confirmed cases every day for the past two weeks.

He said there were now 10 testing laboratories, and though contact tracing had improved, with four in five contacts now being followed up, many more contacts per case needed to be identified.

As for treatment capacity, there are 650 beds in 22 health centres, though around 96 percent of beds are currently occupied.

A further 300 beds are planned.

But the UN health agency's chief warned that the response on the ground was being hampered by mistrust and violence.

"Just this week, an Ebola treatment centre in Ituri province was attacked, resulting in the deaths of two people. The centre was set on fire, and patients fled," he said.

"Such acts not only endanger patients and health workers but also impede efforts to stop transmission and save lives."

WHO emergencies chief Chikwe Ihekweazu lamented that "every time there's an incident, this sets the whole response back."

He said community figures were being invited into treatment centres to see the quality of care provided, and to explain to them what medics were doing and why their support was needed.

New Ebola Treatment Testing Begins in Congo

Suggested for you

More Stories

Truck Catches Fire in Wassa Akropong, Driver Escapes Safely

Fire Destroys Ibadan 'Iso Alagbo' Market, Traders Count Losses

Algeria counts votes for parliamentary election with low turnout

Niamey Angry, Government Says No More Plastic Bags in the City

Nigeria plans to work with Benin and Niger to stop security problems

Photo of the Day: 3rd of July 2026

Discussion